COMPANY
COMPANY
Company Name
Bio Matrix Research, Inc.
Established
March 28, 2002
Capital
¥95,500,000 (as of December 31, 2025)
Representative
Osamu Nomura, CEO
Business Activities
Development, production, and distribution of monoclonal antibodies.
Location
105 Higashi-fukai, Nagareyama-shi, Chiba, Japan, 270-0101
*Enter "105-1 Higashi-fukai" when searching in a map app or site.
Access
・An approximately 15 minute walk from the West Exit of Unga Station (on the Tobu Urban Park Line)
*Please note that taxis may not be readily available at Unga Station.
・An approximately 25 minute taxi ride from Nagareyama-otakanomori Station (on the Tobu Urban Park Line/ Tsukuba Express)
March 2002
Head office established in Noda City, Chiba Prefecture.
Began offering transcription factor antibody development and contract genetic analysis services (microarray/sequencing).
August 2003
Head office functions and sales department relocated to Kashiwa City, Chiba Prefecture.
Laboratory established at Tokatsu Techno Plaza in Kashiwa City, Chiba Prefecture.
January 2004
Sales office opened in Nishi-ku, Osaka.
November 2004
Laboratory established at Todai-Kashiwa Venture Plaza in Kashiwa City, Chiba Prefecture.
March 2006
Head office relocated to Nagareyama City, Chiba Prefecture.
December 2007
Began developing antibody materials for influenza rapid diagnostic kits.
August 2010
Began sales of antibody materials for influenza rapid diagnostic kits.
March 2012
Management structure reorganized. Management resources are focused on development, production, and distribution of antibody materials.
April 2015
Operations are consolidated at the Nagareyama Head Office.
March 2016
Began developing antibody materials for tropical infectious diseases.
March 2018
Began sales of antibodies for detection of malaria.
October 2022
Reconstruction of head office building.
Corporate History
Development of monoclonal antibodies
We independently develop monoclonal antibodies which are essential for diagnosing infectious diseases such as influenza, COVID-19, malaria, and dengue fever. We manufacture these core antibodies that affect the performance of diagnostic kits, at a high level of quality.
We independently develop monoclonal antibodies which are essential for diagnosing infectious diseases such as influenza, COVID-19, malaria, and dengue fever. We manufacture these core antibodies that affect the performance of diagnostic kits, at a high level of quality.
Antibody production and management
We produce antibodies at both our head office and through external contractors. Our products are high-quality with minimal lot-to-lot variability and have earned the trust of kit manufacturers and research institutions worldwide.
We produce antibodies at both our head office and through external contractors. Our products are high-quality with minimal lot-to-lot variability and have earned the trust of kit manufacturers and research institutions worldwide.
Product development and supply for the global market
We supply antibodies not only domestically but also to diagnostic kit manufacturers and research institutions in countries and regions worldwide. We hold an approximately 60% share of the global market share for influenza diagnostic antibodies (according to our own research) and we maintain a world-class supply system.
We supply antibodies not only domestically but also to diagnostic kit manufacturers and research institutions in countries and regions worldwide. We hold an approximately 60% share of the global market share for influenza diagnostic antibodies (according to our own research) and we maintain a world-class supply system.
Joint research and global expansion
We promote the development of products adopted by the WHO (World Health Organization) and research into new antibodies tailored to local needs. We listen directly to customer feedback, including feedback from our development team, and engage in technology partnerships and strategic planning to advance the next generation of diagnostic technologies.
We promote the development of products adopted by the WHO (World Health Organization) and research into new antibodies tailored to local needs. We listen directly to customer feedback, including feedback from our development team, and engage in technology partnerships and strategic planning to advance the next generation of diagnostic technologies.
Providing high-quality monoclonal antibodies
Bio Matrix Research, Inc.
工場で
再生産
Supply of diagnostic kits and infectious disease research
Diagnostic kit manufacturers and research institutions worldwide
Contributing to the early detection and prevention of the spread of infectious diseases
Medical field
Business model
By providing antibodies, which are a critical component in a wide range of products, we contribute to the early detection and prevention of the spread of infectious diseases. That is our business model.
By providing antibodies, which are a critical component in a wide range of products, we contribute to the early detection and prevention of the spread of infectious diseases. That is our business model.
Privacy Policy
All of the content published on this Website is the property of Bio Matrix Research, Inc., and is used in under valid rights and licenses. None of the content of this Website may be reproduced, distributed, or otherwise used without the prior written consent of Bio Matrix Research, Inc., except as permitted by applicable law. The information on this Website is provided for general information purposes. Bio Matrix Research, Inc. makes no representations or warranties regarding its accuracy or completeness, and shall not be liable for any damages arising from the use of this Website, except as dictated by applicable law.
All of the content published on this Website is the property of Bio Matrix Research, Inc., and is used in under valid rights and licenses. None of the content of this Website may be reproduced, distributed, or otherwise used without the prior written consent of Bio Matrix Research, Inc., except as permitted by applicable law. The information on this Website is provided for general information purposes. Bio Matrix Research, Inc. makes no representations or warranties regarding its accuracy or completeness, and shall not be liable for any damages arising from the use of this Website, except as dictated by applicable law.